228 patients with CLL who were registered in the hematology office of the Amur regional consultative clinic in 1995 – 2007 were examined. In the diagnosis of B – CLL, clinical examination data, hemograms, myelograms, trephine biopsy of the Ilium, standard immunophenotype (CD5, CD19, CD20, CD22, CD23) were used. The prevalence of CLL in the Amur Region is in second place among hemoblastosis (18%), second only to acute leukemia. The average annual incidence of this leukemia in the Amur Region is 2 per 100,000 of the population (Table 1). But if we consider the structure of hemoblastosis among the adult population of the region, then CLL is in the first place – 22% of all hemoblastosis, exceeding the prevalence of all other acute and chronic leukemias.The incidence of CLL is detected mainly in the age group of 50–70 years (Table 2). The average age of patients at the time of detection of the disease – 58.5 ± 5.2 years. The distribution of CLL patients depending on gender revealed a slight predominance of men over women .
In Russia, they mainly use the classification of tumors of the lymphatic system proposed by A.I. Vorobiov et al. in 1985 – 2000 . In the classification of 2000. CLL is divided into 7 forms, which allows for differentiated therapy of hemoblastosis. Distribution of CLL patients living in the Amur region, according to the forms of the disease (according to the classification of AI Vorobyev et al. , 2000) .
The life expectancy of patients with a benign form of CLL was 1.5 – 2 decades or more. In these patients, for a long time it was possible to refrain from prescribing a course cytostatic therapy. However, progression of the disease was noted in 70% of patients by the 10th year of observation, and in this connection specific therapy was prescribed. In the past century, with progressive form of CLL, course therapy was administered with chlorambucil. The median survival rate of patients with progressive form of CLL was 94 of the month. In the 90s of the last century, the treatment of patients with the tumor form of CLL began with monotherapy with cyclophosphamide. If there was no effect, they switched to polychemotherapy programs – CP, СОР, СОР, САР. The median survival of patients with the tumor form of CLL was 56 months. Transformation to lymphosarcoma has often been noted.